Question 1

What are Generate Biomedicines, Inc.
's total assets?

Accepted Answer

Generate Biomedicines, Inc.
 (GENB) holds $625.7M in total assets.

Question 2

How much debt does Generate Biomedicines, Inc.
 have?

Accepted Answer

Generate Biomedicines, Inc.
 carries $65.6M in total debt against $514.8M of shareholders' equity, a debt-to-equity ratio of 0.13.

Question 3

How much cash does Generate Biomedicines, Inc.
 have?

Accepted Answer

Generate Biomedicines, Inc.
 holds $160.6M in cash and equivalents.

Question 4

Can Generate Biomedicines, Inc.
 cover its short-term obligations?

Accepted Answer

Its current ratio is 9.17 — current assets exceed current liabilities.

Question 5

Where does Generate Biomedicines, Inc.
's balance sheet data come from?

Accepted Answer

Every line is extracted from Generate Biomedicines, Inc.
's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25
Cash and cash equivalents	$121.65M—
Short-term investments	$99.85M—
Restricted cash	$339K—
Prepaid expenses and other current assets	——
Total current assets	$234.37M—
Property and equipment, net	$29.15M—
Total assets	$330.18M—
Accounts payable	——
Operating lease liabilities, current	$10.7M—
Finance Lease Liability, Current	$4.31M—
Total current liabilities	$82.2M—
Operating lease liabilities, non-current	$50.61M—
Finance lease liabilities	$2.91M—
Other non-current liabilities	$116K—
Total liabilities	$141.55M—
Retained earnings	-$676.29M—
Accumulated other comprehensive income (loss)	$106K—
Total stockholders' equity	-$615.97M-41.8%
Total liabilities and stockholders' equity	$330.18M—
Short- term Investments	$99.85M—
Deferred Tax Assets and Other Non-Current Assets	$6.81M—
Net Investment in Lease	$59.86M—
Operating lease right-of-use assets	$59.86M—
Other non-current assets	$6.81M—
Operating Lease Right-of-Use Assets in Other Assets	$59.86M—
Software and Technology Licenses, Net	$6.81M—
Accrued Expenses And Other Liabilities Current	$42.16M—
Deferred income	$21.19M—
Deferred income	$4.51M—
Total debt	$68.53M—
Additional paid-in capital	$60.19M—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$33K—
Current maturities of long-term debt	$4.31M—
Noncontrolling interests in subsidiaries	-$7.23M—
Warrant To Purchase Convertible Preferred Stock	$1.21M—

Generate Biomedicines, Inc. GENB Balance Sheet Statement

Questions, answered.